 |
MAS Pathfinder Programme listing reflects Finnate's governance-focused design and real-world deployment maturity across regulated financial services
MELBOURNE, Australia, June 8, 2026 /PRNewswire/ -- Centelon announced that Finnate, its enterprise automation platform for financial services, has been officially listed on the PathFin.ai Knowledge Hub — the primary AI solution registry under the Monetary Authority of Singapore (MAS) Pathfinder Programme. The listing follows a structured independent review and verification process assessing Finnate's submitted materials, technical capabilities, and real-world deployment performance in regulated financial environments.
Finnate Listed on PathFin.ai Knowledge Hub
The MAS Pathfinder Programme is designed to accelerate safe and responsible AI adoption across financial institutions in the Asia-Pacific region. Inclusion in the PathFin.ai registry requires vendors to pass a multi-stage vetting process encompassing technical architecture reviews, production case study analysis, and direct verification with existing enterprise clients.
What the Review Examined
The review focused on three operational domains where AI-driven automation carries high regulatory risk:
- Lending and credit decisioning — underwriting velocity, risk transparency, and deterministic audit trail integrity for regulatory reporting
- Digital customer onboarding — end-to-end compliance across identity verification, KYC, and secure data handling
- Document intelligence and workflow automation — extraction, validation, and transformation of unstructured data into governed back-office workflows
Across all three domains, Finnate demonstrated the ability to reduce manual back-office overhead by up to 70% while maintaining full audit traceability — a key requirement for institutions operating under APRA, RBNZ, and equivalent Pacific and Southeast Asian regulatory frameworks.
Why This Listing Matters for Financial Institutions
For compliance officers and technology leaders evaluating AI vendors, PathFin.ai registry status provides a reference point for independent third-party review rather than solely self-reported capability claims. Financial institutions operating in ANZ, Pacific Island markets, and Southeast Asia can reference the listing when conducting internal AI governance due diligence on Centelon's platform.
The Pathfinder Programme review process also considered Finnate's architectural approach to Responsible AI — specifically its use of deterministic processing logic alongside generative AI models to ensure predictable, auditable outputs in regulated workflows.
"For C-suite executives and board directors, this listing is a signal of operational trust," said Ajit Stephen, Group CEO, Centelon. "It demonstrates that Finnate offers a governance-aligned framework for institutions that need to adopt AI with confidence — legally, safely, and at scale."
What Comes Next
Following the review engagement, Centelon will participate in upcoming PathFin.ai knowledge-sharing initiatives and industry webinar series, contributing to cross-industry frameworks for responsible AI deployment in financial services.
The PathFin.ai Knowledge Hub is publicly accessible at https://pathfin.ai.
About Centelon
Centelon is an Australian-headquartered digital product and services company serving enterprise clients across banking, non-bank financial institutions, insurance, telecom, and manufacturing in Australia, Fiji, the Pacific, and Southeast Asia. The company is recognised by Gartner and Everest Group for excellence in digital transformation and banking technology services.
About Finnate
Finnate (www.finnate.ai) is Centelon's next-generation enterprise platform for financial services, delivering Lending Management Systems (LMS), Loan Origination Systems (LOS), and AI-driven Business Process Automation for high-velocity regulated environments.
Media Contact
Centelon Marketing Team
www.centelon.com
marketing@centelon.com
（Related：
Head-to-head Study Validates the Clinical Advantage of New-generation Biased GLP-1: Ecnoglutide Delivers 35% Greater Weight Loss than Semaglutide
｜
Latest
）
